{
    "nct_id": "NCT01320527",
    "title": "A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2016-03-02",
    "description_brief": "Based on prior published pilot studies, the investigators have initiated a larger, multi-site placebo-controlled clinical trial with Alzheimer's disease (AD) patients and individuals diagnosed with Mild Cognitive Impairment (MCI), with the hopes of (1) confirming (or denying) the above promising clinical findings, and (2) determining whether or not our formulation can delay MCI \"conversion\" to AD.",
    "description_detailed": "Preclinical studies with mouse models of of age-related neurodegeneration led us to develop a Nutriceutical Formulation (\"NF\") consisting of 6 over-the-counter vitamins and nutriceuticals, that buffers multiple facets of Alzheimer's disease (AD), including (1) reducing presenilin expression, gamma-secretase activity, Abeta generation and tau phosphorylation, (2) buffering homocysteine and Abeta-induced oxidative damage, (3) reducing aggression, (4) increasing acetylcholine production and improving/maintaining cognitive performance.\n\nA 1-year, open-label trial with NF with mild to moderate AD patients demonstrate improvement in cognitive performance (Dementia Rating Scale, Clock-drawing) within 3-6 months. Caregivers reported maintenance of daily performance and improved mood (ADCS-Activities of Daily Living and NeuroPsychiatric Inventory). A placebo-controlled study with moderate to late-stage AD indicates delayed cognitive decline and maintenance of daily activities. No adverse events were reported.\n\nA multi-site trial with \\>90 individuals aged 45-73 without dementia indicated that NF statistically improved executive function (Trails B-A) vs. placebo within 3 months, which increased further at 6 months. The placebo group demonstrated identical improvement in a 3-month open-label extension. Following NF withdrawal, participants returned to baseline; statistically-significant improvement was restored once NF was individuals resumed.\n\nWe have initiated a larger, multi-site placebo-controlled clinical trial with AD patients and individuals diagnosed with Mild Cognitive Impairment (MCI), with the hopes of (1) confirming (or denying) the above promising clinical findings, and (2) determining whether or not our formulation can delay MCI \"conversion\" to AD.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "folate (vitamin B9)",
        "vitamin B12",
        "alpha-tocopherol (vitamin E)",
        "S-adenosyl methionine (SAMe)",
        "N-acetyl cysteine (NAC)",
        "acetyl-L-carnitine"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The intervention is a defined combination of small-molecule vitamins/nutriceuticals (folate, B12, alpha-tocopherol, S-adenosyl methionine, N\u2011acetyl cysteine, acetyl\u2011L\u2011carnitine). The investigators describe preclinical effects on AD-related biology (presenilin expression, \u03b3\u2011secretase activity, A\u03b2 generation, tau phosphorylation) and the trial aims to test whether the formulation can delay MCI conversion to AD \u2014 i.e., a disease\u2011modifying intent rather than only symptomatic cognitive enhancement. \ue200cite\ue202turn0search1\ue202turn0search7\ue201",
        "Act: I looked up the trial (NCT01320527) and related publications. The Phase II trial lists the nutriceutical formulation components as folate, alpha\u2011tocopherol, B12, S\u2011adenosyl methionine, N\u2011acetyl cysteine, and acetyl\u2011L\u2011carnitine and is described as testing effects on cognition/mood and delaying progression from MCI to AD. Pilot/open\u2011label studies reported cognitive and behavioral benefits. \ue200cite\ue202turn0search7\ue202turn0search3\ue202turn0search0\ue201",
        "Reflect: Given the intervention consists of small-molecule nutritional compounds with preclinical claims of acting on AD pathophysiology and the trial objective to delay conversion from MCI to AD, the best fit among the provided categories is 'disease-targeted small molecule'. If you prefer a more conservative classification emphasizing symptomatic cognitive outcomes rather than disease modification, 'cognitive enhancer' could be argued \u2014 but the trial's stated mechanistic rationale and goal to delay conversion support the disease\u2011targeted small molecule classification. \ue200cite\ue202turn0search1\ue202turn0search7\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The trial tests a defined combination of small-molecule vitamins/nutriceuticals that have preclinical and clinical links to multiple AD-relevant mechanisms: folate/folic acid has been reported to modulate APP secretases and reduce A\u03b2 deposition; SAMe (S-adenosyl methionine) acts as a methyl donor affecting DNA/protein methylation and pathways linked to tau phosphorylation and antioxidant capacity; N\u2011acetylcysteine (NAC) and alpha\u2011tocopherol (vitamin E) act on oxidative stress / glutathione and antioxidant pathways; acetyl\u2011L\u2011carnitine targets mitochondrial/energy metabolism and cholinergic function. These span CADRO categories for amyloid processing, methylation/epigenetic and tau-related processes, oxidative stress, and metabolism/bioenergetics. \ue200cite\ue202turn0search2\ue202turn0search3\ue202turn1search4\ue202turn1search1\ue202turn2search0\ue201",
        "Act: Extracted details from the trial description and literature: components = folate (B9), vitamin B12, alpha\u2011tocopherol (vitamin E), SAMe, NAC, acetyl\u2011L\u2011carnitine. Mechanistic evidence: folate affects BACE1/\u03b3\u2011secretase/presenilin expression and A\u03b2 in APP/PS1 mice; SAMe is central to methylation cycles and linked to tau phosphorylation and glutathione synthesis; NAC is a glutathione precursor and antioxidant reducing oxidative stress; vitamin E is an antioxidant with clinical studies in AD; acetyl\u2011L\u2011carnitine has effects on mitochondrial bioenergetics with mixed clinical evidence. Because these interventions target multiple biological processes rather than a single CADRO pathway, the appropriate assignment is 'R) Multi-target'. \ue200cite\ue202turn0search2\ue202turn0search3\ue202turn1search6\ue202turn1search1\ue202turn2search0\ue201",
        "Reflect: The classification as 'R) Multi-target' best matches the formulation\u2019s multi-component nature and the heterogeneous mechanisms supported by preclinical and clinical literature. One could alternatively emphasize a dominant pathway if only one component were primary, but here multiple components are intended to act on distinct AD-related processes (amyloid/secretases, methylation/tau, oxidative stress, bioenergetics). If future information showed the formulation was being tested solely for symptomatic cognitive enhancement with no disease\u2011modifying intent, a different CADRO subcategory (e.g., D or M) might be considered, but given the trial rationale to delay MCI\u2192AD and the cited mechanistic claims, 'R) Multi-target' is the most specific fit. \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Web search results cited (key sources used):",
        "- Effects of Folic Acid on Secretases Involved in A\u03b2 Deposition in APP/PS1 Mice (PubMed). \ue200cite\ue202turn0search2\ue201",
        "- Protocol / reviews on S\u2011adenosyl methionine (SAMe) and its role in methylation, tau/AD biology (Journal of Prevention of Alzheimer's Disease / PubMed). \ue200cite\ue202turn0search3\ue202turn0search1\ue201",
        "- NAC reviews and studies on NAC as glutathione precursor / antioxidant in neurodegeneration (PubMed reviews). \ue200cite\ue202turn1search4\ue202turn1search6\ue201",
        "- Vitamin E (alpha\u2011tocopherol) clinical trials and meta-analyses in AD (NEJM trial; Cochrane/ systematic reviews). \ue200cite\ue202turn1search1\ue202turn1search8\ue201",
        "- Acetyl\u2011L\u2011carnitine meta-analyses and clinical trials on cognition/mitochondrial effects. \ue200cite\ue202turn2search0\ue202turn2search6\ue201"
    ]
}